



## Delayed large pruritic eruption to the BNT162b2 mRNA vaccine

Takeshi Terashima

Department of Respiratory Medicine, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-0824, Japan



### ARTICLE INFO

#### Article history:

Received 20 September 2021  
Received in revised form 23 September 2021  
Accepted 23 September 2021  
Available online xxxx

#### Keywords:

Delayed cutaneous reaction  
mRNA vaccine  
BNT162b2  
Elderly

The incidence of delayed cutaneous reactions to the SARS-CoV-2 mRNA-1273 vaccine has been reported at 0.8% following the initial dose. The mean age of those exhibiting these reactions is 43 years. The median onset is 8 days post-vaccination, with resolution typically at a median of 6 days post-onset [1]. Although the “COVID arm” has been documented, there are only few detailed reports of it resulting from the administration of the BNT162b2 vaccine [2]. We present a case of such a reaction to BNT162b2 in an elderly patient.

A 75-year-old woman with no prior allergy history exhibited a large, pruritic eruption (60 × 35 mm) 5 days following her first dose of the vaccine (Fig. 1). It was accompanied neither by pain nor induration and resolved spontaneously 6 days following onset. She was encouraged to complete the course, following which there was no recurrence. This report documents that delayed cutaneous reactions may follow BNT162b2 administration, even among elderly patients, but should not discourage vaccination.

E-mail address: [terasima@tdc.ac.jp](mailto:terasima@tdc.ac.jp).



**Fig. 1.** A large, pruritic eruption on the arm following the first dose of BNT162b2 vaccine.

### **Ethical approval**

This study was approved by the ethics committee of Tokyo Dental College.

### **Consent**

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

### **Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### **Author contribution**

TT contributed to the collection of clinical data, data analysis, and manuscript writing. All authors have read and approved the final manuscript.

### **References**

- [1] Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. *N Engl J Med* 2021;384(13):1273–7. <https://doi.org/10.1056/NEJMc2102131>
- [2] Baeck M, Marot L, Belkhir L. Delayed large local reactions to mRNA vaccines. *N Engl J Med* 2021;384(24):98. <https://doi.org/10.1056/NEJMc2104751>